Advances in targeting the extracellular matrix for glaucoma therapy: current updates

Area of Science:

• Ophthalmology
• Cell Biology
• Pharmacology

Background:

• Elevated intraocular pressure (IOP) is a primary risk factor for primary open angle glaucoma (POAG), a leading cause of irreversible blindness.
• Ocular hypertension involves excessive extracellular matrix (ECM) deposition in the trabecular meshwork (TM), increasing aqueous outflow resistance and IOP.
• Therapeutic strategies targeting ECM remodeling in the TM are crucial for managing glaucomatous eyes.

Purpose of the Study:

• To discuss the intricate regulation of ECM in the TM.
• To explore potential therapeutic targets for ECM dysregulation.
• To review current and emerging therapeutic agents for IOP reduction.

Main Methods:

• Review of literature on ECM regulation in the TM.
• Analysis of the role of Transforming Growth Factor-β (TGF-β) in ECM deposition.
• Discussion of signaling pathways involved in ECM remodeling (e.g., Rho GTPase, Wnt, integrin).

Main Results:

• Transforming Growth Factor-β (TGF-β) is identified as a key mediator of ECM deposition in the TM.
• Complex signaling networks, including Rho GTPase, Wnt, and others, influence ECM regulation.
• Various therapeutic agents targeting ECM dysregulation have been investigated.

Conclusions:

• Targeting molecular pathways to modulate ECM deposition and degradation is essential for IOP reduction.
• Developing precise drug delivery systems for specific molecular targets presents a challenge.
• Novel approaches like monoclonal antibodies and nanotechnology show promise for future therapies.